What's Next In: Drug Delivery - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

What's Next In: Drug Delivery

Pharmaceutical Technology

5. S. Kommareddy, S.B. Tiwari, and M.M Amiji, "Long-Circulating Polymeric Nanovectors for tumor-selective Gene Delivery," Technol. Cancer Res. Treat. 4 (6), 615-625 (2005).

6. V.P. Torchilin. "Multifunctional Nanocarriers," Adv. Drug. Deliv. Rev. 58 (14), 1532-1555 (2006).

7. E. Wagner, "Programmed Drug Delivery: Nanosystems for Tumor Targeting," Expert Opin. Biol. Ther. 7 (5), 587-593 (2007).

8. V. Weissig and V.P. Torchilin. "Drug and DNA delivery to Mitochondria," Adv. Drug Deliv. Rev. 49 (1), 1-2 (2001).

9. A. K. Daly, "Individualized Drug Therapy," Curr. Opin. Drug Discov. Devel. 10 (1), 29-36 (2007).

10. J. Woodcock, "The Prospects for "Personalized Medicine" in Drug Development and Drug Therapy," Cli. Pharmaco.l Ther. 81, 164-169 (2007).

Industry experts give their predictions for the next 30 years. Read Editor-in-Chief Michelle Hoffman's introduction here. See what's next in:

Strategy and Regulation
Solid-Dosage Formulation
Drug Delivery
Analytical Testing
Information Technology


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here